SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, today announced it is partnering with AAB Proficiency Testing Service (AAB) for the development and use of preimplantation genetic screening (PGS) reference materials.
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, has signed an agreement with Laboratoire CERBA, a leading European reference laboratory specializing in clinical pathology, to provide custom Seraseq™ Aneuploidy Reference Materials for use with Laboratoire CERBA's non-invasive prenatal testing (NIPT) assay.
SeraCare Life Sciences, a leading partner to clinical laboratories and global in vitro diagnostics manufacturers, announced at the American Association of Clinical Chemistry (AACC) conference today the launch of its newly redesigned website, www.seracare.com.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers and clinical laboratories, announced today that the company's precision medicine business unit has launched a groundbreaking new laboratory QC software specifically for clinical laboratories running next-generation sequencing (NGS)-based assays.
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) have signed of a three-year Cooperative Research And Development Agreement (CRADA) to advance development of circulating tumor DNA (ctDNA) diagnostic assay reference standard materials.
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of AccuPlex Zika Reference Material to fast track the development and validation of PCR-based Zika virus assays.
TOMA Biosciences to use Seraseq™ biosynthetic reference material technology in development and validation of their TOMA OS-Seq™ reagent kits
SeraCare Launches Expanded Offering of Biosynthetic Somatic Tumor Reference Materials for NGS-based Tumor Profiling Assays
SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, today announces the launch of two new circulating tumor DNA (ctDNA) products at the 2016 Molecular Medicine Tri-Conference in San Francisco.
Swift Biosciences, developer of innovative technologies for genomics research, and SeraCare Life Sciences, a manufacturer and leading partner to global in-vitro diagnostics manufacturers, has announced a partnership to accelerate development of a novel circulating tumor DNA reference material.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers and clinical diagnostics laboratories announces two important development milestones to their growing portfolio of next‐generation sequencing (NGS)‐based tools for Precision Medicine.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today that the company’s precision medicine business unit has launched its second product in a growing line of reference materials for next‐generation sequencing (NGS)‐based tumor profiling assays.
SeraCare Life Sciences, a leading partner to clinical laboratories and global in vitro diagnostics manufacturers, announced at the American Association of Clinical Chemistry (AACC) conference today, that it has launched its rebranding initiative as part of the company’s expanding capabilities for the support of advanced diagnostics development.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today at the American Association of Clinical Chemistry (AACC) meeting that it has signed a licensing agreement with the University of California, San Francisco (UCSF) for the use of Trisomy 21 (T21), Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast cell line material as a component for creating “patient-like” reference materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal abnormalities.
Combined Technologies Offer IVD Developers New Tools for Collection, Stabilization and QC
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that the company’s new precision medicine business unit has launched its first product, the Seraseq™ Solid Tumor Mutation Mix—I (AF20); a biosynthetic reference material designed to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.
SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, today announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, to create reference materials and positive controls for cancer assays.
SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced today an expansion and upgrade to their Gaithersburg, MD, R&D facility.
SeraCare Life Sciences, a leading partner to global In Vitro Diagnostics manufacturers, announced the formation of a new business unit focused on the development of technologies and products to help enable the safe and effective expansion of precision medicine-driven diagnostics.
Select your country.
